BMRN: BioMarin Pharmaceutical, Inc.
About
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Current Value
$61.971 Year Return
Current Value
$61.971 Year Return
Key Details
Market Cap
$11.81B
P/E Ratio
37.31
1Y Stock Return
-29.63%
1Y Revenue Growth
19.99%
Dividend Yield
0.00%
Price to Book
2.2
Strategies that include BMRN
Stock's related to BMRN
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TMDX | 39.52% | $2.78B | +22.14% | 0.00% |
| RCUS | 36.53% | $1.33B | +5.07% | 0.00% |
| ITOS | 35.91% | $288.62M | -19.06% | 0.00% |
| PGEN | 34.03% | $228.91M | -28.00% | 0.00% |
| ZUMZ | 33.42% | $409.63M | +17.32% | 0.00% |
| ALDX | 33.05% | $294.18M | +102.46% | 0.00% |
| IONS | 32.45% | $5.33B | -31.18% | 0.00% |
| FOLD | 32.19% | $2.84B | -11.52% | 0.00% |
| MD | 31.94% | $1.25B | +67.55% | 0.00% |
| PLNT | 31.94% | $8.24B | +51.10% | 0.00% |
| CRSP | 31.30% | $4.01B | -30.49% | 0.00% |
| AXGN | 31.16% | $561.11M | +113.93% | 0.00% |
| ARWR | 31.02% | $2.31B | -34.44% | 0.00% |
| CHRS | 30.57% | $94.65M | -58.72% | 0.00% |
| CHE | 30.02% | $8.20B | -5.60% | 0.33% |
| ATNM | 30.01% | $44.30M | -67.05% | 0.00% |
| OLPX | 29.97% | $1.16B | -7.41% | 0.00% |
| AVNT | 29.89% | $4.56B | +44.78% | 2.08% |
| SDGR | 29.85% | $1.38B | -35.46% | 0.00% |
| ENOV | 29.64% | $2.53B | -10.59% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BPT | -0.02% | $24.61M | -66.18% | 0.00% |
| GILT | -0.03% | $310.17M | -13.38% | 0.00% |
| ARCH | -0.04% | $3.03B | +7.87% | 1.26% |
| SMHI | -0.05% | $176.10M | -44.22% | 0.00% |
| CVS | 0.06% | $70.18B | -18.08% | 4.72% |
| WMK | 0.06% | $1.88B | +14.23% | 1.95% |
| EPM | 0.09% | $198.21M | +0.68% | 8.19% |
| GIL | -0.10% | $7.55B | +37.20% | 1.63% |
| PPC | 0.14% | $12.38B | +100.96% | 0.00% |
| GIII | -0.16% | $1.28B | +4.84% | 0.00% |
| FET | -0.16% | $182.04M | -34.05% | 0.00% |
| AMBC | 0.16% | $584.50M | -17.09% | 0.00% |
| KEX | -0.18% | $7.36B | +65.91% | 0.00% |
| GAN | 0.21% | $83.39M | +21.19% | 0.00% |
| ZTO | -0.24% | $12.58B | -4.71% | 4.73% |
| KOF | 0.25% | $4.13B | -7.43% | 4.24% |
| DTM | -0.27% | $10.01B | +81.71% | 2.87% |
| KB | -0.27% | $24.84B | +59.60% | 4.17% |
| ERIE | -0.29% | $19.39B | +46.23% | 1.23% |
| SYPR | 0.30% | $32.23M | -26.32% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ALTO | -18.11% | $106.54M | -39.83% | 0.00% |
| HUSA | -16.19% | $16.69M | -11.56% | 0.00% |
| VTYX | -15.03% | $125.87M | -23.61% | 0.00% |
| NINE | -14.85% | $49.99M | -42.44% | 0.00% |
| STRA | -13.08% | $2.33B | +6.80% | 2.53% |
| IEP | -12.41% | $5.70B | -31.12% | 31.39% |
| VRN | -11.44% | $3.23B | -25.43% | 6.21% |
| SOC | -11.09% | $1.93B | +74.70% | 0.00% |
| COP | -10.93% | $130.16B | -1.63% | 2.59% |
| TNK | -10.70% | $1.48B | -12.01% | 2.31% |
| SW | -10.51% | $13.78B | +15.02% | 1.14% |
| SEG | -10.33% | $319.72M | +12.41% | 0.00% |
| APD | -10.14% | $72.92B | +18.69% | 2.14% |
| INSW | -9.95% | $2.07B | +1.70% | 1.14% |
| CBOE | -9.75% | $21.46B | +15.84% | 1.11% |
| ASPS | -9.21% | $22.36M | -80.26% | 0.00% |
| SU | -9.12% | $52.05B | +23.58% | 3.92% |
| CMG | -9.07% | $80.02B | +33.62% | 0.00% |
| SXC | -8.98% | $1.05B | +39.93% | 3.52% |
| LNG | -8.92% | $49.37B | +24.99% | 0.82% |
ETF's related to BMRN
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PBE | 43.79% | $258.53M | 0.58% |
| IBB | 42.39% | $6.66B | 0.45% |
| FBT | 41.59% | $1.11B | 0.56% |
| BBH | 41.49% | $397.87M | 0.35% |
| GNOM | 39.82% | $70.59M | 0.5% |
| XBI | 38.96% | $6.58B | 0.35% |
| VHT | 38.70% | $17.06B | 0.1% |
| FHLC | 38.51% | $2.73B | 0.084% |
| IYH | 37.06% | $3.19B | 0.39% |
| IHE | 36.15% | $596.23M | 0.39% |
| RSPH | 35.96% | $885.96M | 0.4% |
| PTH | 35.91% | $143.31M | 0.6% |
| FXH | 35.73% | $1.15B | 0.62% |
| XLV | 35.70% | $38.41B | 0.09% |
| IXJ | 35.66% | $3.89B | 0.41% |
| PINK | 35.21% | $161.15M | 0.5% |
| XPH | 35.13% | $157.87M | 0.35% |
| XHE | 31.31% | $213.41M | 0.35% |
| BUFR | 31.22% | $5.69B | 0.95% |
| ARKG | 30.61% | $1.13B | 0.75% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PXE | <0.01% | $117.58M | 0.63% |
| KRBN | 0.01% | $242.47M | 0.85% |
| CPER | -0.11% | $159.52M | 0.97% |
| IBTE | -0.25% | $1.70B | 0.07% |
| XONE | 0.49% | $548.88M | 0.03% |
| RLY | 0.88% | $491.79M | 0.5% |
| PHDG | 1.03% | $113.97M | 0.39% |
| XOP | -1.04% | $2.58B | 0.35% |
| STPZ | 1.21% | $483.31M | 0.2% |
| PREF | -1.38% | $999.92M | 0.55% |
| COPX | 1.43% | $2.40B | 0.65% |
| DBMF | -1.46% | $1.02B | 0.85% |
| FTSM | -1.48% | $6.08B | 0.45% |
| FXN | -1.59% | $416.11M | 0.62% |
| KCCA | -1.65% | $220.51M | 0.87% |
| VTIP | 1.71% | $11.71B | 0.04% |
| IGE | -1.82% | $634.87M | 0.41% |
| URNJ | 1.95% | $283.55M | 0.8% |
| PSCE | -2.20% | $91.62M | 0.29% |
| YEAR | 2.22% | $1.13B | 0.25% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -26.50% | $195.31M | 0.85% |
| BTAL | -17.89% | $388.04M | 1.43% |
| TAIL | -17.59% | $67.98M | 0.59% |
| DBE | -17.07% | $50.13M | 0.77% |
| DBO | -16.57% | $217.57M | 0.77% |
| HIGH | -15.95% | $302.78M | 0.51% |
| PDBC | -14.90% | $4.40B | 0.59% |
| COMT | -14.82% | $829.06M | 0.48% |
| BCD | -14.36% | $245.02M | 0.3% |
| GSG | -14.17% | $914.42M | 0.75% |
| DBC | -13.36% | $1.39B | 0.87% |
| CMDY | -13.06% | $279.14M | 0.28% |
| FTGC | -12.70% | $2.17B | 1.02% |
| GCC | -12.60% | $133.23M | 0.55% |
| KMLM | -11.85% | $353.87M | 0.9% |
| USCI | -11.43% | $185.47M | 1.07% |
| TPMN | -11.16% | $40.60M | 0.65% |
| SOYB | -9.71% | $27.32M | 0.22% |
| BCI | -9.28% | $1.20B | 0.26% |
| CCOR | -9.20% | $109.04M | 1.18% |
News
Yahoo
We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing companies are emerging in the genomics […]
Finnhub
SAN RAFAEL - BioMarin Pharmaceutical Inc. today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO in children with achondroplasia.These results, as well...
Yahoo
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO® (vosoritide) in children with achondroplasia. These results, as well as data from the investigational research program for VOXZOGO in hypochondroplasia, were presented at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting in Liverpool, England, Nov. 16-18, 2024.
Yahoo
Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately.
Yahoo
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The U.S. equity market continued its rise to new record highs, with the S&P 500 Index increasing by 5.89% during this period. In the third quarter, Aristotle Atlantic’s […]
SeekingAlpha
For Q3 2024, Aristotle Atlanticâs Large Cap Growth Composite posted a total return of 1.26% gross of fees, underperforming the 3.19% return of the Russell 1000 Growth Index.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.